Search

Your search keyword '"Centre de Recherche sur le Cancer de Lyon"' showing total 31 results

Search Constraints

Start Over You searched for: Author "Centre de Recherche sur le Cancer de Lyon" Remove constraint Author: "Centre de Recherche sur le Cancer de Lyon"
31 results on '"Centre de Recherche sur le Cancer de Lyon"'

Search Results

1. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications

2. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients

3. Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa

4. Epidemiological, clinical, biological and virological factors influencing the occurrence of hepatocellular carcinoma and validation of predictive scores in 317 HBV-related cirrhotic patients. Prospective study Cir-B nested in the ANRS CO12 CirVir cohort

5. Tailoring a specific medical leadership development program for faculty members: the Lyon-Ottawa experience.

6. Qualitative evaluation of motives for acceptance or refusal of early palliative care in patients included in early-phase clinical trials in a French comprehensive cancer center: the PALPHA study.

7. Comparison of Pathway Referrals for Liver Fibrosis Risk Stratification Performed in Diabetology and Nutrition Clinics.

8. A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics.

9. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension.

10. Immune checkpoint inhibitors and hospitalization at home in France.

11. Zeb1 represses TCR signaling, promotes the proliferation of T cell progenitors and is essential for NK1.1 + T cell development.

12. Subclinical and Clinical Outcomes in Patients Coinfected With HIV and Chronic Hepatitis B Virus From Clinical Outpatient Centers in France: Protocol for an Ambispective, Longitudinal Cohort Study.

13. The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma.

14. Intraoperative dermoscopy features of subungual squamous cell carcinoma: a study of 53 cases.

15. Correlation of serum hepatitis B core-related antigen with hepatitis B virus total intrahepatic DNA and covalently closed circular-DNA viral load in HIV-hepatitis B coinfection.

16. Hepatitis B virus activity in untreated hepatitis B e antigen-negative human immunodeficiency virus-hepatitis B virus co-infected patients from sub-Saharan Africa.

17. Hepatitis B virus genotype G and liver fibrosis progression in chronic hepatitis B and human immunodeficiency virus coinfection.

18. [Risk of hepatocellular carcinoma after hepatitis C virus cure with direct-acting antivirals: the next challenges].

19. Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication.

21. Clinical Outcomes during Treatment Interruptions in Human Immunodeficiency Virus-Hepatitis B Virus Co-infected Patients from Sub-Saharan Africa.

22. Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients.

23. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.

24. Renal outcomes after up to 8 years of tenofovir exposure in HIV-HBV-coinfected patients.

25. Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients.

27. Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.

28. Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML).

29. Identifying patients infected with hepatitis B virus in sub-Saharan Africa: potential for misclassification.

30. HTLV-1-infected CD4+ T-cells display alternative exon usages that culminate in adult T-cell leukemia.

31. HTLV-1 bZIP factor HBZ promotes cell proliferation and genetic instability by activating OncomiRs.

Catalog

Books, media, physical & digital resources